Greenwich LifeSciences, Inc.
GLSI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $4 | $4 | $4 | $4 |
| Gross Profit | -$4 | -$4 | -$4 | -$4 |
| % Margin | – | – | – | – |
| R&D Expenses | $12,952 | $7,699 | $6,476 | $3,560 |
| G&A Expenses | $3,060 | $1,629 | $1,565 | $1,038 |
| SG&A Expenses | $3,060 | $1,629 | $1,565 | $1,038 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $16,012 | $9,328 | $8,040 | $4,598 |
| Operating Income | -$16,012 | -$9,328 | -$8,040 | -$4,598 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $223 | $436 | $215 | $27 |
| Pre-Tax Income | -$15,789 | -$8,892 | -$7,825 | -$4,571 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$15,789 | -$8,892 | -$7,825 | -$4,571 |
| % Margin | – | – | – | – |
| EPS | -1.21 | -0.69 | -0.61 | -0.35 |
| % Growth | -75.4% | -13.1% | -74.3% | – |
| EPS Diluted | -1.21 | -0.69 | -0.61 | -0.35 |
| Weighted Avg Shares Out | 13,015 | 12,848 | 12,914 | 12,944 |
| Weighted Avg Shares Out Dil | 13,015 | 12,848 | 12,914 | 12,944 |
| Supplemental Information | – | – | – | – |
| Interest Income | $223 | $436 | $215 | $27 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $4 | $4 | $4 | $4 |
| EBITDA | -$15,785 | -$9,324 | -$8,037 | -$4,594 |
| % Margin | – | – | – | – |